PITTSBURGH & LONDON--(BUSINESS WIRE)--Helomics, a privately-held, comprehensive personalised healthcare company (headquartered in Pittsburgh, Pennsylvania) that develops innovative next-generation diagnostics for the oncology field, announced today that it is delighted to be supporting the UK’s Personalised Healthcare Alliance. As a founding contributor to the Alliance, Helomics joins the likes of AstraZeneca, Biogen Idec, Cancer Research UK, Epistem, Horizon Discovery, Myeloma UK and MRC Technology in aiding the development of this important initiative. The priorities of the Alliance are to promote the UK’s many strengths in the personalised healthcare sector, to bring a growing community of “challenge agents” together for the widespread dialogue that will be fundamental to UK leadership in this space, to serve as an independent presence that reflects the breadth and value of the UK’s contribution, and to help forge better health for UK citizens and UK plc.
Help employers find you! Check out all the jobs and post your resume.
